Share of costs to R&D of Novo Nordisk 2008-2018

Novo Nordisk is a Danish pharmaceutical company founded in 1923. The company's key product is diabetes medication, but does also produce pharmaceuticals for other use. Their expenditure share spent on research and development fluctuated during the period from 2008 to 2018, with a peak in 2008, with 17.2 percent of the costs. In 2018, the share of expenditure spent on research and development was 13.2 percent.

Share of costs spent on research and development of Novo Nordisk from 2008 to 2018

Share of costs
--
--
--
--
--
--
--
--
--
--
--
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

January 2019

Region

Denmark

Survey time period

2008 to 2018

Supplementary notes

Some figures have been taken from previous publications.

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.

Statistics on "Pharmaceutical trends in Europe"

Further Content: You might find this interesting as well

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.